Estrogen alters the splicing of type 1 corticotropin-releasing hormone receptor in breast cancer cells

Science Signaling

Volumn 6, Issue 282, 2013, Pages

  Lal, Suchita ^a   Allan, Anna ^a   Markovic, Danijela ^b   Walker, Rosemary ^c   Macartney, James ^a   Europe, Nick Finner ^d   Tyson, Alison Capper ^d   Grammatopoulos, Dimitris K ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b California Institute of Technology   (United States)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; ESTROGEN; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CELL INVASION; CONTROLLED STUDY; DRUG EFFECT; EXON; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; RNA EXTRACTION;

ALTERNATIVE SPLICING; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL MOVEMENT; CORTICOTROPIN-RELEASING HORMONE; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MCF-7 CELLS; MICROSCOPY, CONFOCAL; MITOGEN-ACTIVATED PROTEIN KINASES; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PHOSPHORYLATION; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84880899655     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003926     Document Type: Article

References (61)

1. M. H. Antoni, S. K. Lutgendorf, S. W. Cole, F. S. Dhabhar, S. E. Sephton, P. G. McDonald, M. Stefanek, A. K. Sood, The influence of bio-behavioural factors on tumour biology: Pathways and mechanisms. Nat. Rev. Cancer 6, 240-248 (2006).
2. P. H. Thaker, A. K. Sood, Neuroendocrine influences on cancer biology. Semin. Cancer Biol. 18, 164-170 (2008).
3. E. M. Reiche, S. O. Nunes, H. K. Morimoto, Stress, depression, the immune system, and cancer. Lancet Oncol. 5, 617-625 (2004).
4. A. Slominski, B. Zbytek, A. Pisarchik, R. M. Slominski, M. A. Zmijewski, J.Wortsman, CRH functions as a growth factor/cytokine in the skin. J. Cell. Physiol. 206, 780-791 (2006).
5. L. Antonova, K. Aronson, C. R. Mueller, Stress and breast cancer: From epidemiology to molecular biology. Breast Cancer Res. 13, 208 (2011).
6. J. Tjuvajev, Y. Kolesnikov, R. Joshi, J. Sherinski, L. Koutcher, Y. Zhou, C. Matei, J. Koutcher, M. J. Kreek, R. Blasberg, Anti-neoplastic properties of human corticotropin releasing factor: Involvement of the nitric oxide pathway. In Vivo 12, 1-10 (1998).
7. A. Androulidaki, E. Dermitzaki, M. Venihaki, E. Karagianni, O. Rassouli, E. Andreakou, C. Stournaras, A. N. Margioris, C. Tsatsanis, Corticotropin Releasing Factor promotes breast cancer cell motility and invasiveness. Mol. Cancer 8, 30 (2009).
8. A. Arranz, M. Venihaki, B. Mol, A. Androulidaki, E. Dermitzaki, O. Rassouli, J. Ripoll, E. N. Stathopoulos, R. P. Gomariz, A. N. Margioris, C. Tsatsanis, The impact of stress on tumor growth: Peripheral CRF mediates tumor-promoting effects of stress. Mol. Cancer 9, 261 (2010).
9. L. Jin, C. Chen, R. Guo, R. Wan, S. Li, Role of corticotropin-releasing hormone family peptides in androgen receptor and vitamin D receptor expression and translocation in human breast cancer MCF-7 cells. Eur. J. Pharmacol. 684, 27-35 (2012).
10. Z. Hao, Y. Huang, J. Cleman, I. S. Jovin, W. W. Vale, T. L. Bale, F. J. Giordano, Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc. Natl. Acad. Sci. U.S.A. 105, 3939-3944 (2008).
11. G. Graziani, L. Tentori, I. Portarena, M. Barbarino, G. Tringali, G. Pozzoli, P. Navarra, CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143, 807-813 (2002).
12. V. Minas, A. Rolaki, S. N. Kalantaridou, J. Sidiropoulos, S. Mitrou, G. Petsas, U. Jeschke, E. A. Paraskevaidis, G. Fountzilas, G. P. Chrousos, N. Pavlidis, A. Makrigiannakis, Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br. J. Cancer 97, 637-645 (2007).
13. J. C. Reubi, B. Waser, W. Vale, J. Rivier, Expression of CRF1 and CRF2 receptors in human cancers. J. Clin. Endocrinol. Metab. 88, 3312-3320 (2003).
14. G. Graziani, L. Tentori, A. Muzi, M. Vergati, G. Tringali, G. Pozzoli, P. Navarra, Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype. Mol. Cell. Endocrinol. 264, 44-49 (2007).
15. D. R. Ciocca, L. A. Puy, L. C. Fasoli, O. Tello, J. C. Aznar, F. E. Gago, S. I. Papa, R. Sonego, Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormonereleasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients. Breast Cancer Res. Treat. 15, 175-184 (1990).
16. A. Kaprara, K. Pazaitou-Panayiotou, M. C. Chemonidou, T. C. Constantinidis, M. Lambropoulou, M. Koffa, A. Kiziridou, S. Kakolyris, A. Kortsaris, E. Chatzaki, Distinct distribution of corticotropin releasing factor receptors in human breast cancer. Neuropeptides 44, 355-361 (2010).
17. I. Gamez, R. P. Ryan, L. D. Reid, S. M. Routt, B. A. Hollister, Corticorelin acetate, a synthetic corticotropin-releasing factor with preclinical antitumor activity, alone and with bevacizumab, against human solid tumor models. Cancer Chemother. Pharmacol. 67, 1415-1422 (2011).
18. B. Westley, H. Rochefort, Estradiol induced proteins in the MCF7 human breast cancer cell line. Biochem. Biophys. Res. Commun. 90, 410-416 (1979).
19. K. L. Parham, S. Zervou, E. Karteris, R. D. Catalano, R. W. Old, E. W. Hillhouse, Promoter analysis of human corticotropin-releasing factor (CRF) type 1 receptor and regulation by CRF and urocortin. Endocrinology 145, 3971-3983 (2004).
20. S. S. Azab, S. A. Salama, A. B. Abdel-Naim, A. E. Khalifa, E. El-Demerdash, A. Al-Hendy, 2-Methoxyestradiol and multidrug resistance: Can 2-methoxyestradiol chemosensitize resistant breast cancer cells? Breast Cancer Res. Treat. 113, 9-19 (2009).
21. G. G. Liu, E. Fong, X. Zeng, GNCPro: Navigate human genes and relationships through net-walking. Adv. Exp. Med. Biol. 680, 253-259 (2010).
22. R. A. Mendoza, E. E. Moody, M. I. Enriquez, S. M. Mejia, G. Thordarson, Tumorigenicity of MCF-7 human breast cancer cells lacking the p38a mitogen-activated protein kinase. J. Endocrinol. 208, 11-19 (2011).
23. L. Yang, H. C. Dan, M. Sun, Q. Liu, X. M. Sun, R. I. Feldman, A. D. Hamilton, M. Polokoff, S. V. Nicosia, M. Herlyn, S. M. Sebti, J. Q. Cheng, Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 64, 4394-4399 (2004).
24. J. Dong, J. Peng, H. Zhang,W. H.Mondesire,W. Jian, G. B. Mills,M. C. Hung, F. Meric-Bernstam, Role of glycogen synthase kinase 3b in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 65, 1961-1972 (2005).
25. D. A. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich, B. A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
26. T. M. Thornton, G. Pedraza-Alva, B. Deng, C. D. Wood, A. Aronshtam, J. L. Clements, G. Sabio, R. J. Davis, D. E. Matthews, B. Doble, M. Rincon, Phosphorylation by p38 MAPK as an alternative pathway for GSK3b inactivation. Science 320, 667-670 (2008).
27. K. M. Jacobs, S. R. Bhave, D. J. Ferraro, J. J. Jaboin, D. E. Hallahan, D. Thotala, GSK-3b: A bifunctional role in cell death pathways. Int. J. Cell Biol. 2012, 930710 (2012).
28. D. Wu, W. Pan, GSK3: A multifaceted kinase in Wnt signaling. Trends Biochem. Sci. 35, 161-168 (2010).
29. T. Schlange, Y. Matsuda, S. Lienhard, A. Huber, N. E. Hynes, Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 9, R63 (2007).
30. J. I. Yook, X. Y. Li, I. Ota, C. Hu, H. S. Kim, N. H. Kim, S. Y. Cha, J. K. Ryu, Y. J. Choi, J. Kim, E. R. Fearon, S. J. Weiss, A Wnt-Axin2-GSK3b cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol. 8, 1398-1406 (2006).
31. Kip1 phosphorylation through PTEN inhibition. Oncogene 28, 824-831 (2009).
32. K. Solly, X. Wang, X. Xu, B. Strulovici, W. Zheng, Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev. Technol. 2, 363-372 (2004).
33. C. h. V. Rao, X. Li, S. K. Manna, Z. M. Lei, B. B. Aggarwal, Human chorionic gonadotropin decreases proliferation and invasion of breast cancer MCF-7 cells by inhibiting NF-kB and AP-1 activation. J. Biol. Chem. 279, 25503-25510 (2004).
34. M. Uchino, H. Kojima, K. Wada, M. Imada, F. Onoda, H. Satofuka, T. Utsugi, Y. Murakami, Nuclear b-catenin and CD44 upregulation characterize invasive cell populations in nonaggressive MCF-7 breast cancer cells. BMC Cancer 10, 414 (2010).
35. Z. Zhu, A. R. Boobis, R. J. Edwards, Identification of estrogen-responsive proteins in MCF-7 human breast cancer cells using label-free quantitative proteomics. Proteomics 8, 1987-2005 (2008).
36. P. C. Cheng, H. K. Chang, S. H. Chen, Quantitative nanoproteomics for protein complexes (QNanoPX) related to estrogen transcriptional action. Mol. Cell. Proteomics 9, 209-224 (2010).
37. E. Karteris, D. Markovic, J. Chen, E. W. Hillhouse, D. K. Grammatopoulos, Identification of a novel corticotropin-releasing hormone type 1b-like receptor variant lacking exon 13 in human pregnant myometrium regulated by estradiol-17b and progesterone. Endocrinology 151, 4959-4968 (2010).
38. A. Punn, M. A. Levine, D. K. Grammatopoulos, Identification of signaling molecules mediating corticotropin-releasing hormone-R1a-mitogen-activated protein kinase (MAPK) interactions: The critical role of phosphatidylinositol 3-kinase in regulating ERK1/2 but not p38 MAPK activation. Mol. Endocrinol. 20, 3179-3195 (2006).
39. C. M. Revankar, D. F. Cimino, L. A. Sklar, J. B. Arterburn, E. R. Prossnitz, A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307, 1625-1630 (2005).
40. S. B. Cheng, C. T. Graeber, J. A. Quinn, E. J. Filardo, Retrograde transport of the transmembrane estrogen receptor, G-protein-coupled-receptor-30 (GPR30/GPER) from the plasma membrane towards the nucleus. Steroids 76, 892-896 (2011).
41. V. Filippov, M. Filippova, P. J. Duerksen-Hughes, The early response to DNA damage can lead to activation of alternative splicing activity resulting in CD44 splice pattern changes. Cancer Res. 67, 7621-7630 (2007).
42. C. C. Jiang, F. Lai, K. H. Tay, A. Croft, H. Rizos, T. M. Becker, F. Yang, H. Liu, R. F. Thorne, P. Hersey, X. D. Zhang, Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death Dis. 1, e69 (2010).
43. C. Ghigna, C. Valacca, G. Biamonti, Alternative splicing and tumor progression. Curr. Genomics 9, 556-570 (2008).
44. L. Cartegni, J. Wang, Z. Zhu, M. Q. Zhang, A. R. Krainer, ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res. 31, 3568-3571 (2003).
45. A. Pisarchik, A. Slominski, Corticotropin releasing factor receptor type 1: Molecular cloning and investigation of alternative splicing in the hamster skin. J. Invest. Dermatol. 118, 1065-1072 (2002).
46. A. Pisarchik, A. T. Slominski, Alternative splicing of CRH-R1 receptors in human and mouse skin: Identification of new variants and their differential expression. FASEB J. 15, 2754-2756 (2001).
47. D. Markovic, M. Vatish, M. Gu, D. Slater, R. Newton, H. Lehnert, D. K. Grammatopoulos, The onset of labor alters corticotropin-releasing hormone type 1 receptor variant expression in human myometrium: Putative role of interleukin-1b. Endocrinology 148, 3205-3213 (2007).
48. S. K. Calderwood, Heat shock proteins in breast cancer progression-A suitable case for treatment? Int. J. Hyperthermia 26, 681-685 (2010).
49. A. M. Oliveira, J. S. Ross, J. A. Fletcher, Tumor suppressor genes in breast cancer: The gatekeepers and the caretakers. Am. J. Clin. Pathol. 124, S16-S28 (2005).
50. T. Jin, I. G. Fantus, J. Sun, Wnt and beyond Wnt: Multiple mechanisms control the transcriptional property of b-catenin. Cell. Signal. 20, 1697-1704 (2008).
51. D. Zhang, L. L. Wong, E. S. Koay, Phosphorylation of Ser78 of Hsp27 correlated with HER-2/neu status and lymph node positivity in breast cancer. Mol. Cancer 6, 52 (2007).
52. T. D. King, M. J. Suto, Y. Li, The wnt/b-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J. Cell. Biochem. 113, 13-18 (2012).
53. S. C. Baumgarten, J. Frasor, Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol. Endocrinol. 26, 360-371 (2012).
54. W. W. Kuang, D. A. Thompson, R. V. Hoch, R. J. Weigel, Differential screening and suppression subtractive hybridization identified genes differentially expressed in an estrogen receptor-positive breast carcinoma cell line. NucleicAcids Res. 26, 1116-1123 (1998).
55. S. Tozlu, I. Girault, S. Vacher, J. Vendrell, C. Andrieu, F. Spyratos, P. Cohen, R. Lidereau, I. Bieche, Identification of novel genes that co-cluster with estrogen receptor a in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer 13, 1109-1120 (2006).
56. D. Markovic, H. Lehnert, M. A. Levine, D. K. Grammatopoulos, Structural determinants critical for localization and signaling within the seventh transmembrane domain of the type 1 corticotropin releasing hormone receptor: Lessons from the receptor variant R1d. Mol. Endocrinol. 22, 2505-2519 (2008).
57. D. Markovic, D. K. Grammatopoulos, Focus on the splicing of secretin GPCRs transmembranedomain 7. Trends Biochem. Sci. 34, 443-452 (2009).
58. M. J. Pajares, T. Ezponda, R. Catena, A. Calvo, R. Pio, L. M. Montuenga, Alternative splicing: An emerging topic in molecular and clinical oncology. Lancet Oncol. 8, 349-357 (2007).
59. E. Kim, A. Goren, G. Ast, Insights into the connection between cancer and alternative splicing. Trends Genet. 24, 7-10 (2008).
60. C. J. David, J. L. Manley, Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev. 24, 2343-2364 (2010).
61. A. Hanamura, J. F. Cáceres, A. Mayeda, B. R. Franza Jr., A. R. Krainer, Regulated tissue-specific expression of antagonistic pre-mRNA splicing factors. RNA 4, 430-444 (1998).